1. Home
  2. CLW vs URGN Comparison

CLW vs URGN Comparison

Compare CLW & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLW
  • URGN
  • Stock Information
  • Founded
  • CLW 2005
  • URGN 2004
  • Country
  • CLW United States
  • URGN United States
  • Employees
  • CLW N/A
  • URGN N/A
  • Industry
  • CLW Paper
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • CLW Basic Materials
  • URGN Health Care
  • Exchange
  • CLW Nasdaq
  • URGN Nasdaq
  • Market Cap
  • CLW 501.0M
  • URGN 465.9M
  • IPO Year
  • CLW N/A
  • URGN 2017
  • Fundamental
  • Price
  • CLW $31.06
  • URGN $11.84
  • Analyst Decision
  • CLW Buy
  • URGN Strong Buy
  • Analyst Count
  • CLW 1
  • URGN 5
  • Target Price
  • CLW $37.00
  • URGN $44.50
  • AVG Volume (30 Days)
  • CLW 314.3K
  • URGN 326.4K
  • Earning Date
  • CLW 02-13-2025
  • URGN 03-13-2025
  • Dividend Yield
  • CLW N/A
  • URGN N/A
  • EPS Growth
  • CLW N/A
  • URGN N/A
  • EPS
  • CLW 0.88
  • URGN N/A
  • Revenue
  • CLW $2,211,900,000.00
  • URGN $89,363,000.00
  • Revenue This Year
  • CLW N/A
  • URGN $12.21
  • Revenue Next Year
  • CLW N/A
  • URGN $46.19
  • P/E Ratio
  • CLW $34.79
  • URGN N/A
  • Revenue Growth
  • CLW 58.65
  • URGN 15.64
  • 52 Week Low
  • CLW $23.97
  • URGN $9.78
  • 52 Week High
  • CLW $57.13
  • URGN $20.70
  • Technical
  • Relative Strength Index (RSI)
  • CLW 52.23
  • URGN 54.97
  • Support Level
  • CLW $30.22
  • URGN $10.77
  • Resistance Level
  • CLW $33.27
  • URGN $11.65
  • Average True Range (ATR)
  • CLW 0.97
  • URGN 0.51
  • MACD
  • CLW -0.15
  • URGN 0.15
  • Stochastic Oscillator
  • CLW 36.80
  • URGN 70.47

About CLW Clearwater Paper Corporation

Clearwater Paper Corp is engaged in the manufacturing and selling of private label tissue, paperboard, and pulp-based products. The company has two reportable segments namely the consumer products segment which manufactures and sells a complete line of at-home tissue products as well as AFH products. The pulp and paperboard segment manufactures and markets bleached paperboard for the high-end segment of the packaging industry as well as offers services that include custom sheeting, slitting and cutting of paperboard. It generates maximum revenue from Pulp and Paperboard segment. Geographically, it derives maximum revenue from the United States.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: